Amplia Therapeutics Limited

Amplia Therapeutics partners with Lilly on lung cancer combination trial

2026-08-04 09:06:00

Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF) has signed a clinical collaboration agreement with Eli Lilly and Company to evaluate its lead drug...

Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly's Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer

2026-08-04 08:45:00

HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company's investigational FAK inhibitor narmafotinib in combination with Lilly's late‑stage investigational next generation KRAS inhibitor olomorasib The collaboration is underpinned by narmafotinib's growing base of clinical evidence and a strong scientific rationale that FAK activation is a key driver of resistance to KRAS G12C inhibitors The collaboration further extends narmafotinib beyond pancreatic and ovarian cancer into NSCLC, broadening Amplia's clinical footprint and addressable opportunity Melbourne, Australia, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has entered into a Clinical Trial Collaboration and Supply Agreement (“CTCSA”) with Eli Lilly & Company (“Lilly”), to evaluate the combination of Amplia's investigational FAK inhibitor, narmafotinib, with Lilly's investigational KRAS G12C inhibitor, olomorasib. The Phase 1b/2b clinical trial will evaluate the safety and efficacy of this novel targeted therapy combination as a second line treatment in patients with advanced stage non-small cell lung cancer (NSCLC).

Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online

2026-07-31 08:45:00

HIGHLIGHTS A manuscript describing comprehensive preclinical studies of narmafotinib in models of pancreatic cancer is now available online. The findings provide further evidence of narmafotinib's ability to target several important drivers of pancreatic cancer progression, including fibrosis, chemotherapy resistance and metastatic spread.

Amplia Announces Publication of New FAK Inhibitor Patent Application

2026-07-09 08:45:00

HIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by Amplia Application expands Amplia's intellectual property portfolio supporting its FAK inhibitor program If granted, patent protection for the new molecules and their use would extend to 2046 New compounds broaden pipeline optionality and may support future development and partnering opportunities Melbourne, Australia, July 09, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce publication of a new patent application describing chemically novel inhibitors of focal adhesion kinase (FAK) discovered by the Company. The patent application further expands Amplia's FAK intellectual property portfolio and, if granted, would provide protection for the novel molecules described, and their use, out to 2046.

Amplia Announces Appointment of Brett Carter to Board

2026-07-07 08:45:00

Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce the appointment of Mr Brett Carter to the Board of Directors as non-executive director, effective from 6 July 2026.

Amplia Announces Changes to Board's Leadership Roles

2026-07-06 08:45:00

Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and succession plan.

Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer

2026-06-22 08:45:00

Melbourne, Australia, June 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or the “Company”) provides a letter to shareholders from CEO and Managing Director Dr. Chris Burns outlining the potential for the Company's best-in-class FAK inhibitor narmafotinib in combination with the emerging KRAS inhibitor class following exciting new data presented at the American Society of Clinical Oncology Annual Meeting earlier this month:

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

2026-05-19 08:45:00

HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study Patient enrolment planned to begin by Q4 2026 Melbourne, Australia, May 19, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it is initiating a Phase 2b study of narmafotinib in pancreatic cancer exploring a new dosing regimen. Designed in alignment with FDA feedback, the study will form the basis – and first stage – of a registrational study in this indication given the high existing unmet need for innovative treatments.